Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VENCLEXTA (Abbvie Pty Ltd)
Product name
VENCLEXTA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
130 working days (255)
Active ingredients
venetoclax
Registration type
EOI
Indication
VENCLEXTA (tablets) in combination with rituximab is now also indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.